Cpl Biologicals Profile
Key Indicators
- Authorised Capital ₹ 95.00 Cr
- Paid Up Capital ₹ 20.00 Cr
- Company Age 15 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -70.23%
- Profit Growth -367.58%
- Ebitda -315.16%
- Net Worth -82.46%
- Total Assets -8.41%
About Cpl Biologicals
Cpl Biologicals Private Limited (CBPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 March 2009 and has a history of 15 years and ten months. Its registered office is in Ahmedabad, Gujarat, India.
The Corporate was formerly known as Cpl Biologicals Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 95.00 Cr and a paid-up capital of Rs 20.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Cpl Biologicals Private Limited India is Mr Banerjee as CFO. Rajiv Modi, Amitabha Banerjee, Ramesh Choksi, and One other member serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U01403GJ2009PTC056409
- Company No.
056409
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Mar 2009
- Date of AGM
14 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Cpl Biologicals?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Mr Banerjee | CFO | 22-Aug-2016 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Amitabha Banerjee | Whole-Time Director and Cfo | 03-May-2018 | Current |
Rajiv Modi | Director | 24-Mar-2009 | Current |
Ramesh Choksi | Director | 06-May-2014 | Current |
Rajiv Modi | Director | 05-Aug-2024 | Current |
Financial Performance of Cpl Biologicals.
Cpl Biologicals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 70.23% decrease. The company also saw a substantial fall in profitability, with a 367.58% decrease in profit. The company's net worth observed a substantial decline by a decrease of 82.46%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Cpl Biologicals?
In 2023, Cpl Biologicals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cpl Biologicals?
Cpl Biologicals has a workforce of 24 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cpl Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cpl Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.